SCHEMBL5542383

SCHEMBL5542383

Fc1ccc(CN[CH]c2ccccc2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.46
BCHE P06276 2/20 0.46
BACE1 P56817 2/20 0.46
IDO1 P14902 2/20 0.40
AGXT P21549 2/20 0.40
KDM4E B2RXH2 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
EGFR P00533 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
NFE2L2 Q16236 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537898 0.84 KDM1A (0.50) SMN1; SMN2MEN1NPC1ALDH1A1MAPT
SCHEMBL5543788 0.82 LMNA (0.47) IDO1MEN1ALDH1A1MAPTHPGD
SCHEMBL24186105 0.75 IDO1 (0.44) ACHEBCHEBACE1IDO1AGXT
SCHEMBL5541864 0.75 IDO1 (0.44) ACHEBCHEBACE1IDO1AGXT
SCHEMBL5534736 0.75 PLA2G1B (0.49) ACHEBCHEBACE1KDM4ENPC1
SCHEMBL5536817 0.75 NFE2L2 (0.47) IDO1AGXTMAPTRAB9ANFE2L2
SCHEMBL5544342 0.75 NFE2L2 (0.39) MEN1GAAHPGDKMT2ANFE2L2
SCHEMBL5540801 0.74 CCNE2 (0.38) IDO1EGFRGAANFE2L2
SCHEMBL30339701 0.74 L3MBTL1 (0.52) ACHEBCHEBACE1MEN1ALDH1A1
SCHEMBL28052988 0.74 IDO1 (0.43) ACHEBCHEBACE1IDO1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ACHE 4670/4885BCHE 4833/4885BACE1 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.